Crescendo Bioscience, Inc. (NASDAQ:MYGN)

CAPS Rating: 3 out of 5

Myriad Genetics is focused on developing and marketing novel molecular diagnostic products.

Recs

0
Player Avatar marsuculix (< 20) Submitted: 2/7/2013 4:37:30 AM : Outperform Start Price: $25.89 MYGN Score: -14.00

promising business - solid fundamentals...

Featured Broker Partners


Advertisement